Paul Bisaro
CIK 1237253 · Executive Chairman · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$23.77M
Companies
11
Total Filings
133
Lifetime Open-Market Net
-$38.45M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MYGN | Director | 157,142 | $3.26 | $512.3K | $27.6K | 6 | 2026-06-05 |
| ZTS | Director | 27,862 | $72.66 | $2.02M | $151.8K | 24 | 2026-05-13 |
| Keenova Therapeutics plc (MNK) Delisted | Director | 71,131 | $0.34 | $24.2K | $42.3K | 5 | 2023-06-29 |
| TXMD | Director | 5,922 | $2.07 | $12.3K | $96.5K | 7 | 2022-10-03 |
| AMRX | Executive Chairman | 29,454 | $18.14 | $534.3K | $203.5K | 4 | 2019-05-09 |
| Allergan plc (AGN) Delisted | Director | 383,729 | — | — | -$16.97M | 13 | 2018-05-04 |
| ZBH | Director | — | $96.55 | — | $0 | 15 | 2017-04-04 |
| Impax Laboratories, LLC (IPXL) Delisted | President and CEO | — | — | — | $0 | 1 | 2017-03-29 |
| ACT | Exec Chairman | 422,531 | $48.96 | $20.69M | $0 | 2 | 2015-03-09 |
| Actavis, Inc. (WPI) Delisted | President & CEO | 307,339 | — | — | $0 | 12 | 2012-03-16 |
| BARR PHARMACEUTICALS INC (BRL) Delisted | 133,078 | — | — | -$22.00M | 25 | 2007-10-24 |
Recent Filings · Page 10 of 14
133 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-09-17 | — | Gift (G) | −7,000 | $0 | |
| 2013-08-22 | — | Sell (S) | −50,000 | -$6.77M | |
| 2013-08-09 | — | Mixed | +203,139 | -$27.72M | |
| 2013-03-08 | — | Grant (A) | +52,505 | $0 | |
| 2013-03-07 | — | Tax (F) | −19,068 | -$1.65M | |
| 2013-03-05 | — | Tax (F) | −24,683 | -$2.11M | |
| 2012-03-16 | Actavis, Inc. (WPI) Delisted | Tax (F) | −6,521 | -$386.1K | EDGAR |
| 2012-03-12 | Actavis, Inc. (WPI) Delisted | Grant (A) | +61,933 | $0 | EDGAR |
| 2012-02-28 | Actavis, Inc. (WPI) Delisted | Tax (F) | −16,759 | -$974.9K | EDGAR |
| 2011-09-06 | Actavis, Inc. (WPI) Delisted | Tax (F) | −8,386 | -$556.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.